Back to School: How biopharma can reboot drug development. Access exclusive analysis here

OxiGene, Techniclone deal

The companies formed a joint venture, Arcus Therapeutics LLC, that will combine OXGN's tubulin-binding

Read the full 145 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE